middle.news
How Clarity’s Cu-SAR-bisPSMA Is Changing Prostate Cancer Detection
9:50am on Tuesday 17th of March, 2026 AEDT
•
Healthcare
Read Story
How Clarity’s Cu-SAR-bisPSMA Is Changing Prostate Cancer Detection
9:50am on Tuesday 17th of March, 2026 AEDT
Key Points
Cu-SAR-bisPSMA detects 2.6 times more lesions than Ga-PSMA-11 in low PSA prostate cancer recurrence
78% of patients had positive scans with Cu-SAR-bisPSMA versus 36% with standard imaging
Next-day imaging with Cu-SAR-bisPSMA changed patient management in 44% of cases
Data accepted for publication in European Urology, impact factor 25.2
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Clarity Pharmaceuticals (ASX:CU6)
OPEN ARTICLE